Celyad Oncology SA (NASDAQ:CYAD – Get Rating)'s share price passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.91 and traded as low as $1.71. Celyad Oncology shares last traded at $1.80, with a volume of 3,476 shares traded.
Celyad Oncology Stock Performance
The company has a current ratio of 1.71, a quick ratio of 2.58 and a debt-to-equity ratio of 0.05. The company's 50-day simple moving average is $1.91 and its 200 day simple moving average is $1.98.
About Celyad Oncology
(Get Rating)
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.
See Also
- Get a free copy of the StockNews.com research report on Celyad Oncology (CYAD)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.